Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer

Pakistan Journal of Medical Sciences

Volumn 29, Issue 5, 2013, Pages

  Bi, Jian Wei ^a   Mao, Yi Min ^a   Sun, Yu Xia ^a   Liu, Shi Qing ^b  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Advanced non small cell lung cancer; ERCC1; mRNA; Outcome; RRM1

Indexed keywords

CARBOPLATIN; CISPLATIN; COMPLEMENTARY DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DNA DETERMINATION; DRUG RESPONSE; ERCC1 GENE; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GENE; GENE EXPRESSION REGULATION; HUMAN; LONG TERM SURVIVAL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; PROGRESSION FREE SURVIVAL; RRM1 GENE;

EID: 84881487917     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.295.3812     Document Type: Article

References (16)

1. International Agency for Research on Cancer (2008). Lung cancer incidence, Mortality and Prevalence Worldwide in 2008. http://globocan.iarc.fr/ factsheet.asp
2. Matakidou A, El-Galta R, Webb EL, Rudd MF, Bridle H, Eisen T, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16(19):2333-2340.
3. Zhou W, Gurubhagavatula S, Liu G. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10(15):4939-4943.
4. Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65(3):377-382.
5. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009;64(1):98-104.
6. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer. 2000;87(12):881-886.
7. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005;1(1):7-17.
8. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, et al. Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy. J Thorac Oncol. 2013;8(5):582-586.
9. Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, et al. Prognostic significance of ERCC1, RRM1 & BRCA1 in surgically-treated patients with nonsmall cell lung cancer. Anticancer Res. 2012;32(11):5003-5010.
10. Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, et al. Expression of RRM1 and ERCC1 genes in tumor tissues & peripheral blood lymphocytes of advanced non-small cell lung cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012;41(5):540-546.
11. Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 2011;28(4):1411-1417.
12. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, et al. ERCC1/ BRCA1 expression & gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108(8):1695-1703.
13. Yu D, Shi J, Sun T, Du X, Liu L, Zhang X, et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol. 2012;33(3):877-884.
14. Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer. 2012;48(18):3378-3385.
15. Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, et al. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/ carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;69(5):1277-1287.
16. Ren SX, Li AW, Zhou SW, Zhang L, Wang YS, Li B, et al. Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1. Chin J Cancer Res. 2012;24(3):226-231.